vs
HUDSON TECHNOLOGIES INC（HDSN）与REGENXBIO Inc.（RGNX）财务数据对比。点击上方公司名可切换其他公司
HUDSON TECHNOLOGIES INC的季度营收约是REGENXBIO Inc.的1.5倍（$44.4M vs $30.3M），HUDSON TECHNOLOGIES INC净利率更高（-19.4% vs -221.3%，领先201.9%），REGENXBIO Inc.同比增速更快（43.0% vs 28.2%），HUDSON TECHNOLOGIES INC自由现金流更多（$-33.7M vs $-52.8M），过去两年REGENXBIO Inc.的营收复合增速更高（39.4% vs -17.5%）
哈德逊科技是总部位于美国的可持续制冷剂解决方案供应商，提供原生及回收再生制冷剂、制冷剂回收处理和合规支持服务，主要服务北美市场，核心客户覆盖暖通空调、商用制冷和工业冷却领域，助力客户向低全球变暖潜能值制冷剂转型。
REGENXBIO Inc.是一家临床阶段生物技术企业，专注于开发针对罕见及严重遗传疾病的突破性基因疗法。公司拥有专有的腺相关病毒载体技术，既向全球生物制药合作伙伴提供技术授权，也自主推进多疾病领域的基因疗法管线研发。
HDSN vs RGNX — 直观对比
营收规模更大
HDSN
是对方的1.5倍
$30.3M
营收增速更快
RGNX
高出14.8%
28.2%
净利率更高
HDSN
高出201.9%
-221.3%
自由现金流更多
HDSN
多$19.1M
$-52.8M
两年增速更快
RGNX
近两年复合增速
-17.5%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $44.4M | $30.3M |
| 净利润 | $-8.6M | $-67.1M |
| 毛利率 | 8.0% | — |
| 营业利润率 | -25.2% | -190.0% |
| 净利率 | -19.4% | -221.3% |
| 营收同比 | 28.2% | 43.0% |
| 净利润同比 | -236.6% | -31.2% |
| 每股收益（稀释后） | $-0.19 | $-1.30 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收HDSNRGNX
| Q4 25 | $44.4M | $30.3M | ||
| Q3 25 | $74.0M | $29.7M | ||
| Q2 25 | $72.8M | $21.4M | ||
| Q1 25 | $55.3M | $89.0M | ||
| Q4 24 | $34.6M | $21.2M | ||
| Q3 24 | $61.9M | $24.2M | ||
| Q2 24 | $75.3M | $22.3M | ||
| Q1 24 | $65.3M | $15.6M |
净利润HDSNRGNX
| Q4 25 | $-8.6M | $-67.1M | ||
| Q3 25 | $12.4M | $-61.9M | ||
| Q2 25 | $10.2M | $-70.9M | ||
| Q1 25 | $2.8M | $6.1M | ||
| Q4 24 | $-2.6M | $-51.2M | ||
| Q3 24 | $7.8M | $-59.6M | ||
| Q2 24 | $9.6M | $-53.0M | ||
| Q1 24 | $9.6M | $-63.3M |
毛利率HDSNRGNX
| Q4 25 | 8.0% | — | ||
| Q3 25 | 32.0% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 21.8% | — | ||
| Q4 24 | 16.7% | 70.2% | ||
| Q3 24 | 25.7% | 48.8% | ||
| Q2 24 | 30.0% | 52.5% | ||
| Q1 24 | 32.8% | 72.6% |
营业利润率HDSNRGNX
| Q4 25 | -25.2% | -190.0% | ||
| Q3 25 | 18.9% | -176.3% | ||
| Q2 25 | 17.5% | -296.3% | ||
| Q1 25 | 5.6% | 13.6% | ||
| Q4 24 | -9.4% | -242.1% | ||
| Q3 24 | 11.3% | -256.6% | ||
| Q2 24 | 17.0% | -251.3% | ||
| Q1 24 | 19.6% | -408.8% |
净利率HDSNRGNX
| Q4 25 | -19.4% | -221.3% | ||
| Q3 25 | 16.7% | -208.3% | ||
| Q2 25 | 14.0% | -331.8% | ||
| Q1 25 | 5.0% | 6.8% | ||
| Q4 24 | -7.4% | -241.3% | ||
| Q3 24 | 12.6% | -246.3% | ||
| Q2 24 | 12.7% | -237.7% | ||
| Q1 24 | 14.7% | -405.4% |
每股收益（稀释后）HDSNRGNX
| Q4 25 | $-0.19 | $-1.30 | ||
| Q3 25 | $0.27 | $-1.20 | ||
| Q2 25 | $0.23 | $-1.38 | ||
| Q1 25 | $0.06 | $0.12 | ||
| Q4 24 | $-0.05 | $-0.99 | ||
| Q3 24 | $0.17 | $-1.17 | ||
| Q2 24 | $0.20 | $-1.05 | ||
| Q1 24 | $0.20 | $-1.38 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $39.5M | $230.1M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $243.4M | $102.7M |
| 总资产 | $318.6M | $453.0M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资HDSNRGNX
| Q4 25 | $39.5M | $230.1M | ||
| Q3 25 | $89.7M | $274.2M | ||
| Q2 25 | $84.3M | $323.3M | ||
| Q1 25 | $81.0M | $267.9M | ||
| Q4 24 | $70.1M | $234.7M | ||
| Q3 24 | $56.5M | $255.5M | ||
| Q2 24 | $30.5M | $290.4M | ||
| Q1 24 | $10.6M | $338.7M |
股东权益HDSNRGNX
| Q4 25 | $243.4M | $102.7M | ||
| Q3 25 | $265.9M | $161.5M | ||
| Q2 25 | $254.8M | $213.7M | ||
| Q1 25 | $246.8M | $274.2M | ||
| Q4 24 | $245.8M | $259.7M | ||
| Q3 24 | $253.9M | $301.4M | ||
| Q2 24 | $248.7M | $348.3M | ||
| Q1 24 | $238.6M | $390.7M |
总资产HDSNRGNX
| Q4 25 | $318.6M | $453.0M | ||
| Q3 25 | $338.9M | $525.2M | ||
| Q2 25 | $317.9M | $581.0M | ||
| Q1 25 | $307.9M | $490.9M | ||
| Q4 24 | $302.7M | $466.0M | ||
| Q3 24 | $309.4M | $519.1M | ||
| Q2 24 | $300.9M | $569.4M | ||
| Q1 24 | $294.2M | $629.2M |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-32.5M | $-52.3M |
| 自由现金流经营现金流 - 资本支出 | $-33.7M | $-52.8M |
| 自由现金流率自由现金流/营收 | -75.8% | -174.0% |
| 资本支出强度资本支出/营收 | 2.5% | 1.7% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-8.2M | $-126.4M |
8季度趋势，按日历期对齐
经营现金流HDSNRGNX
| Q4 25 | $-32.5M | $-52.3M | ||
| Q3 25 | $8.8M | $-56.0M | ||
| Q2 25 | $6.4M | $-49.3M | ||
| Q1 25 | $14.2M | $33.6M | ||
| Q4 24 | $20.7M | $-31.6M | ||
| Q3 24 | $30.3M | $-40.5M | ||
| Q2 24 | $41.8M | $-45.5M | ||
| Q1 24 | $-933.0K | $-55.5M |
自由现金流HDSNRGNX
| Q4 25 | $-33.7M | $-52.8M | ||
| Q3 25 | $6.7M | $-56.5M | ||
| Q2 25 | $5.9M | $-49.7M | ||
| Q1 25 | $12.7M | $32.6M | ||
| Q4 24 | $19.2M | $-32.7M | ||
| Q3 24 | $28.6M | $-40.9M | ||
| Q2 24 | $40.6M | $-46.0M | ||
| Q1 24 | $-1.9M | $-56.0M |
自由现金流率HDSNRGNX
| Q4 25 | -75.8% | -174.0% | ||
| Q3 25 | 9.1% | -189.9% | ||
| Q2 25 | 8.2% | -232.8% | ||
| Q1 25 | 23.0% | 36.6% | ||
| Q4 24 | 55.3% | -154.2% | ||
| Q3 24 | 46.2% | -168.9% | ||
| Q2 24 | 54.0% | -206.2% | ||
| Q1 24 | -2.9% | -358.5% |
资本支出强度HDSNRGNX
| Q4 25 | 2.5% | 1.7% | ||
| Q3 25 | 2.8% | 1.7% | ||
| Q2 25 | 0.6% | 1.8% | ||
| Q1 25 | 2.5% | 1.2% | ||
| Q4 24 | 4.5% | 5.1% | ||
| Q3 24 | 2.7% | 1.3% | ||
| Q2 24 | 1.5% | 2.1% | ||
| Q1 24 | 1.5% | 3.6% |
现金转化率HDSNRGNX
| Q4 25 | — | — | ||
| Q3 25 | 0.71× | — | ||
| Q2 25 | 0.63× | — | ||
| Q1 25 | 5.13× | 5.53× | ||
| Q4 24 | — | — | ||
| Q3 24 | 3.88× | — | ||
| Q2 24 | 4.36× | — | ||
| Q1 24 | -0.10× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
HDSN
| Products | $43.1M | 97% |
| Services | $1.3M | 3% |
RGNX
| Novartis Gene Therapies | $24.2M | 80% |
| Nippon Shinyaku Collaboration And License Agreement | $4.3M | 14% |
| Nippon Shinyaku Services | $1.4M | 5% |
